This protocol presents the establishment of deep hypothermic circulatory arrest in rats, which can be applied to investigate systemic inflammatory response syndrome, ischemia/reperfusion injury, oxidative stress, neuroinflammation, etc.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
This protocol presents the establishment of deep hypothermic circulatory arrest in rats, which can be applied to investigate systemic inflammatory response syndrome, ischemia/reperfusion injury, oxidative stress, neuroinflammation, etc.
Deep hypothermic circulatory arrest (DHCA) is routinely applied during surgeries for complex congenital heart disease and aortic arch disease. The present study aims to provide a method for establishing DHCA in rats. To evaluate the impact of the DHCA process on vital signs, a normal temperature cardiopulmonary bypass (CPB) rat model without circulatory arrest was used as a control. As expected, DHCA led to a significant decrease in body temperature and mean arterial blood pressure. The blood gas analysis indicated that DHCA increased lactic acid levels but did not influence the blood pH and the concentrations of hemoglobin, hematocrit, Na+, Cl−, K+, and glucose. Furthermore, compared with the normal temperature CPB rats, the results of the transmission electron microscopy showed a mild increase in hippocampal autophagosomes in the DHCA rats.
Deep hypothermic circulatory arrest (DHCA) has been used in cardiac surgery since 19531. DHCA involves reducing the patient's core temperature to profoundly hypothermic levels (15-22 °C) before globally interrupting the blood flow to the body2. The circulatory arrest can provide a relatively bloodless operating field. Deep hypothermia decreases the metabolism, especially in the brain and myocardium, which is an effective method of protection against ischemia3. DHCA is commonly applied during surgeries for complex congenital heart disease, aortic arch disease, and even renal or adrenal tumors with a vena cava thrombus4,5. Therefore, establishing DHCA animal models provides an important reference for the refinement of the procedure and the prevention of complications in clinical settings.
Although models can be established with canines6, rabbits7, and other animals, it is preferable to use rats because of their operability and low cost. The DHCA rat model was described for the first time in 2006 by Jungwirth et al.8. It was found that the duration of circulatory arrest had an impact on the neurologic outcomes. Since then, DHCA rat models have been investigated broadly. It has been clarified that DHCA could provoke systemic inflammatory response syndrome (SIRS)9. In subsequent studies, pharmacologists found that the DHCA-related neuroinflammation induced by SIRS could be attenuated by resveratrol10 and triptolide11. Our team also found that DHCA-related neuroinflammation could be attenuated by inhibiting the cold-inducible RNA-binding protein12. In the cardiovascular system, superoxide dismutase has a cardioprotective effect on ischemia/reperfusion (I/R) injuries during DHCA13. These results expanded the understanding of DHCA-related pathophysiologic processes and offered new directions for improving the outcomes of DHCA. However, the results regarding endotoxemia, oxidative stress, and autophagy after DHCA are inconclusive. DHCA uses the same operational technology as the cardiopulmonary bypass (CPB)14, but its management strategy is different, and the steps to generate DHCA differ across various teams8,9,10,11. The present study aims to provide a method for establishing the DHCA procedure in rats.
Access restricted. Please log in or start a trial to view this content.
The protocols underwent an institutional review and received approval from the Institutional Animal Care and Use Committee, Fuwai Hospital, Chinese Academy of Medical Sciences (FW-2021-0005). All the experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
NOTE: Male Sprague-Dawley rats (weight: 500-600 g, age: 12-14 weeks) were kept under standard laboratory conditions with free access to food and water. The rats were randomly allocated into two groups (n = 6, each group): the DHCA group, and the normal temperature CPB group (NtCPB group).
1. Preparatory work
2. Anesthesia and cannulation
3. DHCA initiation
4. Cooling
5. Deep hypothermic circulatory arrest
6. Warm-up and reperfusion
7. Weaning off the CPB
Access restricted. Please log in or start a trial to view this content.
As the control group, the normal temperature CPB (NtCPB) rats without circulatory arrest showed a stable mean arterial blood pressure (MAP) and body temperature during the whole procedure, while the MAP of the DHCA rats decreased during the cardiac arrest (p < 0.01, Figure 3A). The temperature of the DHCA rats dropped quickly during the cooling phase and recovered gradually during the rewarming phase. When weaning the rats off the DHCA circuits, the temperature of the DHCA rats r...
Access restricted. Please log in or start a trial to view this content.
Cannulation is the most fundamental procedure for establishing DHCA in rats. Before cannulation, soaking the artery with 0.5 mL of 2% lidocaine will make it easier to cannulate. After cannulation, heparinization with 500 IU/kg heparin via the external jugular vein is necessary to avoid microthrombus formation17. We have repeatedly found that this dose of heparin can achieve the goal of an activated clotting time (ACT) >480 s. The rewarming period is the most difficult part. It took mor...
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
The authors thank Liang Zhang for helping to collect the video data during the experiment. This study was supported by the National Natural Science Foundation of China (Grant number: 82070479) and the Fundamental Research Funds for the Central Universities (Grant number: 3332022128).
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Heat Exchanger | Xi’an Xijing Medical Appliance Co., Ltd | Animal-M | |
| Membrane Oxygenator | Dongguan Kewei Medical Instrument Co., Ltd. | Micro-M | |
| Monitor | Chengdu Techman Co., Ltd | BL-420s | |
| Roller Pump | Changzhou Prefluid Technology Co.,Ltd | BL100 | |
| SD Rat | HFK Bioscience Co.,Ltd. | / | |
| Sevoflurane | Maruishi Pharmaceutical Co. Ltd | H20150020 | |
| Shaver | Hangzhou Huayuan Pet Products Co.,Ltd. | / | |
| Vaporizer | SPACECABS | / | |
| Ventilator | Shanghai Alcott Biotech Co., Ltd | ALC-V8S | |
| Water Tank | Maquet Critical Care AB | Jostra HCU20-600 |
Access restricted. Please log in or start a trial to view this content.